A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control
- 33 Downloads
Small bowel adenocarcinomas are rare. There is no definite consensus as to whether they should be treated in a manner similar to gastric or to colon cancer. We report the case of a young woman with a primary jejunal adenocarcinoma, bilateral ovary metastases, and peritoneal dissemination. First- and second-line chemotherapy for the gastric cancer failed. She was then treated with the immune checkpoint inhibitor nivolumab and had temporary improvement in her condition. To the best of our knowledge, this is the first case wherein nivolumab has been used to treat small bowel adenocarcinoma.
KeywordsSmall bowel adenocarcinoma Signet ring cell carcinoma Immune checkpoint inhibitors
Compliance with ethical standards
Conflict of interest
All authors declare no conflicts of interest.
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent was obtained from all patients for being included in the study.
- 15.Howe JR, Karnell LH, Menck HR, et al. Adenocarcinoma of the small bowel: review of the National Cancer Data Base. Cancer 1985-1995;86:2693–2706.Google Scholar
- 24.Clinical Practice Guidelines in Oncology Colon cancer version 1.2019-March 15,2019. (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed 2019 March 28.
- 32.Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.CrossRefGoogle Scholar
- 33.Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (ver. 5).Google Scholar
- 37.De Wolf K, Kruse V, et al. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;31;15(1):21.Google Scholar